( - Clinical activity reported against CT...)CuraGen Presents Update on Clinical Development Program for,Belinostat,Health

BRANFORD, Conn., June 12, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation , a clinical-stage biopharmaceutical company focused on oncology, presented today an update on the clinical development program for belinostat, a histone deacetylase (HDAC) inhibitor, and reported updated results suggesting clinical activity of belinostat against cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and ovarian cancers.

A conference call is being hosted at 8:30 a.m. Eastern time on June 12, 2007, to review these results including data presented at the 2007 Pan Pacific Lymphoma Conference being held this week in Maui, HI, and data presented at the 2007 American Society of Clinical Oncology (ASCO) meeting.

"We are very impressed by the emerging data on intravenous belinostat in the treatment of solid and hematologic cancers, both as a single agent and in combination with other chemotherapeutic agents. These results, along with additional data actively being generated, are helping us to refine the potential indications for belinostat and to enable us to develop an appropriate plan for our Phase III program," commented Frank Armstrong, M.D., President and Chief Executive Officer of CuraGen.

CLN-6: Phase II trial evaluating intravenous belinostat for T-cell Lymphomas

The interim results reported on 14 patients with CTCL and 12 patients with PTCL. In the CTCL arm in patients who had received an average of six prior lines of therapy, four of 14 patients achieved an objective response for an objective response rate of 29% including one complete response (CR) and three partial responses (PR). Time to response ranged from 8-57 days. As demonstrated by a decrease in SWAT score, 77% of evaluable patients showed an improvement in skin burden of CTCL. Five out of six patients with significant pruritus at baseline had a cl
'"/>